Related Experiment Videos

Antihypertensive action of acebutolol (Sectral) when used concomitantly with hydrochlorothiazide

P A Mitenko, J K McKenzie, J J Brossard

    British Journal of Clinical Pharmacology
    |February 1, 1982
    PubMed

    Insights

    Hydrochlorothiazide effectively lowers blood pressure in patients with essential hypertension. Adding acebutolol further reduces blood pressure, demonstrating its efficacy as an anti-hypertensive agent.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Essential hypertension is a common condition requiring effective treatment.
    • Diuretics and beta-blockers are established anti-hypertensive drug classes.

    Purpose of the Study:

    • To evaluate the anti-hypertensive effects of hydrochlorothiazide alone and in combination with acebutolol.
    • To assess the dose-response relationship of acebutolol when added to hydrochlorothiazide therapy.

    Main Methods:

    • A placebo-controlled study involving 18 patients with moderately severe essential hypertension.
    • Patients received hydrochlorothiazide, followed by the addition of acebutolol in escalating doses.
    • Blood pressure was monitored in a supine position throughout the study.

    Main Results:

    • Hydrochlorothiazide (100 mg daily) reduced mean supine blood pressure from 163/107 mmHg to 150/103 mmHg.
    • Adding acebutolol (up to 800 mg daily) further decreased mean supine blood pressure to 137/95 mmHg.
    • Increased acebutolol dosage (up to 2000 mg daily) in 13 patients lowered blood pressure to 132/92 mmHg.

    Conclusions:

    • Hydrochlorothiazide demonstrates significant anti-hypertensive effects in essential hypertension.
    • Combination therapy with hydrochlorothiazide and acebutolol provides additive blood pressure reduction.
    • Acebutolol is effective in further controlling hypertension not adequately managed by hydrochlorothiazide alone.

    Related Concept Videos

    Antihypertensive Drugs: Thiazide-Class Diuretics01:15

    Antihypertensive Drugs: Thiazide-Class Diuretics

    Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
    Antihypertensive Drugs: Action of β1 Blockers01:17

    Antihypertensive Drugs: Action of β1 Blockers

    β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...